Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received approval for SUPRAX (Cefixime) Capsules 400 mg from the United States Food and Drugs Administration (FDA). Lupin expects to commence shipping the product in the near future.
The approval will expand Lupin’s range of SUPRAX dosage forms available to treat the approved indications in appropriate patients. SUPRAX is currently available as 100 mg/5ml and 200 mg/5ml suspensions as well as 400 mg tablets.
Commenting on the approval, Mr. Nilesh Gupta, Group President & Executive Director, Lupin Limited, said: “We are happy to receive this approval. The new dosage form will add to our growing SUPRAX franchise and gives health care providers and patients a new formulation to treat the indicated infections. The approval of SUPRAX capsules is one more example of our ongoing commitment to serving our customers and addressing their needs.”